AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01349582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative management
Description: conservative management is watchful observation of the aneurysm until indication for intervention arises
Study NCT01349582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular coiling
Description: standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
Study NCT01349582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: balloon parent vessel occlusion
Description: sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
Study NCT01349582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical clipping
Description: clipping of the aneurysm following invasive brain surgery
Study NCT02607332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00514436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma coaching
Description: Inperson contact followed by telephone with approach by issues raised by family
Study NCT01825655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Study NCT01825655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo or sugar pill
Study NCT04019652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: Single, oral administration; 10-mg or 40-mg dose
Study NCT04019652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Single, oral administration; 400 mg-tablet
Study NCT01941355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training component
Description: The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
Study NCT04019652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching moxifloxacin tablet
Description: Placebo tablets matching moxifloxacin tablets
Study NCT04019652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching CS-3150
Description: Placebo tablets matching CS-3150 tablets
Study NCT03450915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-001
Description: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
Study NCT01941355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educative component
Description: The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
Study NCT03450915 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% sodium chloride (NaCl)
Study NCT04169061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Acthar gel for subcutaneous injection
Study NCT01667393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IDEV SUPERA Stent
Study NCT01667393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty
Study NCT01867814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Description: Pneumoperitoneum 15 mmHg and 10 mmHg
Study NCT02615795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele Monitoring, using Tunstall monitoring device
Description: Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
Study NCT02909413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoﬂurane
Description: Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
Study NCT03828240 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HIP fracture REhabilitation Programme for the elderly with hip fractures
Description: Eight-week activity-based intervention for elderly with hip fractures; one intervention during the hospital stay, four interventions at the elderly's municipality.
Study NCT01820780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides levels to J7 and J14
Study NCT03271788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness, MBSR
Description: Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
Study NCT03307954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso Therapy (Exoskeleton Suit)
Study NCT03307954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy
Study NCT01480557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liquefaction
Description: Cataract extraction surgery type
Study NCT01480557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Torsional ip
Description: A type cataract surgery using torsional ip technology
Study NCT04358198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence
Description: The AI algorithm based on the convolutional neural network (CNN) will be used for analysis the pictures of gastric intestinal metaplasia and normal mucosa. Then AI will be used as a diagnostic tool for GIM during routine endoscopy by using pathology as a gold standard.
Study NCT00824928 — intervention group
Intervention type: PROCEDURE
Intervention: Cryoablation / Cryotherapy
Description: Salvage Cryoablation of the prostate
Study NCT01921946 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan
Study NCT01921946 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Study NCT04527328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKST1210
Description: AKST1210
Study NCT02975336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951
Description: Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
Study NCT04113148 — intervention group
Intervention type: OTHER
Intervention: Physiological measurements from heel
Description: Measurements of blood flow, tissue oxygen saturation, temperature, pressure
Study NCT01682070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUBLIVAC FIX phleum prat.
Description: Comparison of different dosages to placebo
Study NCT01682070 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00844285 — intervention group
Intervention type: DRUG
Intervention: Cimzia
Description: The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
Study NCT02735018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:200,000
Description: Inferior alveolar nerve block with Epinephrine 1:200.000
Study NCT01900678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VytronUS Ablation System
Description: Pulmonary vein isolation.
Study NCT03894098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: High ankle nerve block
Study NCT03894098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: High ankle nerve block
Study NCT01929096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Edaravone Injection
Study NCT04527328 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control (No Intervention)
Description: A covered surrogate object of similar size and shape as the investigational device
Study NCT04527328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Hemodialysis
Study NCT04527328 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hemodialysis
Description: Hemodialysis
Study NCT00258388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: custirsen sodium
Description: 640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)
Study NCT00258388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
Study NCT00258388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 5mg PO BID
Study NCT01608490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RePneu Lung Volume Reduction Coil System
Description: The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
Study NCT03433547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buckle
Description: Surgical procedures of macular buckling
Study NCT01374217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
Study NCT01374217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered as it was prior to study entry.
Study NCT01374217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as it was prior to study entry.
Study NCT01374217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin will be administered as it was prior to study entry.
Study NCT01929096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edaravone Injection
Study NCT02971397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT02971397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02595840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study NCT02595840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT03433547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Surgical procedures of small gauge vitrectomy
Study NCT03433547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limbal paracentesis
Description: Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis
Study NCT03433547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gas injection
Description: Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.
Study NCT03433547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peeling internal limiting membrane
Description: Peeling internal limiting membrane with forceps
Study NCT03433547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gas tamponade
Description: Filling the vitreous cavity with gas (C3F8, 14%)
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: A 20 mg tablet of morphine
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching tablet of placebo
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cowhage (Mucuna Pruriens)
Description: 25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cowhage (Mucuna Pruriens)
Description: 25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cowhage (Mucuna Pruriens)
Description: 25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study NCT04115462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cowhage (Mucuna Pruriens)
Description: 25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study NCT05595200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Level III portable sleep study
Description: Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
Study NCT00222976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
Study NCT03920501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Critical Care
Description: Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
Study NCT02971397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02971397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04091958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoralis myo-glandular flap reconstruction.
Description: Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
Study NCT01899547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic-assisted rectal resection
Description: Arm I: Patients undergo laparoscopic-assisted rectal resection.
Study NCT01899547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional open rectal resection
Description: Arm II: Patients undergo conventional open rectal resection.
Study NCT02961270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
Study NCT00283400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% human albumin
Description: 25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
Study NCT04605536 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: animation videos
Description: watch animation videos about capsule endoscopy
Study NCT04605536 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: explanation about endoscopy endoscopy
Description: Give general explanations about endoscopy endoscopy
Study NCT03379506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR FDC Tablet
Description: Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
Study NCT03379506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matched to EBR/GZR FDC tablet.
Study NCT03379506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir Oral Granules
Description: Participants 3 to \<12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
Study NCT03379506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir Oral Granules
Description: Participants 3 to \<12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
Study NCT00980421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron Supplementation
Description: Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
Study NCT00980421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplementation
Description: Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
Study NCT01603030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 0,5% + prednisolone 1%
Description: 1 gtt, 4x/day, 15 days
Study NCT01603030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin/prednisolone combination
Description: 1 gtt, 4x/day, 15 days
Study NCT04488848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bolus glucose
Description: bolus Glucose
Study NCT04488848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: continuous clucose
Description: continuous clucose
Study NCT03922633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion.
Study NCT03922633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.
Study NCT01750632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Description: The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.